Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab-Reference-Cited by-同舟云学术

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab

Published:2010 Issue:1 Volume:25 Page:86
ISSN:1226-3303
Container-title:The Korean Journal of Internal Medicine
language:en
Short-container-title:Korean J Intern Med

Author:

Lim Kyu-Hyoung¹,Yoon Ho-Il²,Kang Young Ae²,Lee Keun-Wook²,Kim Jee Hyun²,Bang Soo-Mee²,Lee Jae Ho²,Lee Choon-Taek¹²,Lee Jong Seok¹²

Affiliation:

1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

2. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

Publisher

Korean Association of Internal Medicine

Link

http://synapse.koreamed.org/pdf/10.3904/kjim.2010.25.1.86

Reference19 articles.

1. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2. Tolerability and safety of rituximab (MabThera®)

3. Tumor necrosis factor α release is a major biological event associated with rituximab treatment

4. Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis

5. First-Line Treatment with Brief-Duration Chemotherapy Plus Rituximab in Elderly Patients with Intermediate-Grade Non-Hodgkin's Lymphoma: Phase II Trial

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma;Frontiers in Oncology;2022-06-01

2. Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival;Leukemia Research;2021-12

3. Age-Related Disease Risks in Younger versus Older B-Cell Non-Hodgkin's Lymphoma Survivors;Cancer Epidemiology Biomarkers & Prevention;2021-11-03

4. Incidence and risk factors of pneumonia in diffuse large B-cell lymphoma patients receiving first line R-CHOP/R-CHOP-like immunochemotherapy: a retrospective study of 287 patients in single center;Annals of Palliative Medicine;2021-11

5. Multiple blood parameters may serve as a warning to immunochemotherapy-related interstitial lung disease in B-cell lymphoma;Annals of Palliative Medicine;2021-09